Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
GILD Gilead Sciences
86.050-0.310-0.36%
Close
02/07 16:00 ET
86.0500.0000.00%
Pre Mkt Price 02/08 04:00 ET
High
86.690
Open
86.600
Turnover
627.59M
Low
85.380
Pre Close
86.360
Volume
7.30M
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Gilead Sciences Inc. Stock Falls Tuesday, Underperforms Market
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) sank 0.36% to $86.05 Tuesday, on what proved to be an all-aroun
UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating
UBS Adjusts Gilead Sciences Price Target to $90 From $85, Maintains Neutral Rating
Maxim Group Keeps Their Buy Rating on Gilead Sciences (GILD)
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75
Gilead Sciences, Inc. (NASDAQ:GILD) will increase its dividend on the 30th of March to $0.75, which is 2.7% higher than last year's payment from the same period of $0.73.
Gilead Sciences (NASDAQ:GILD) Given New $112.00 Price Target at Piper Sandler
Gilead Sciences (NASDAQ:GILD – Get Rating) had its price target raised by Piper Sandler from $111.00 to $112.00 in a research note issued to investors on Friday, The Fly reports. The brokerage curren
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hologic (HOLX) and Zimmer Biomet Holdings (ZBH)
Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) rallied 2.20% to $86.36 Monday, on what proved to be an all-aro
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Edmond DE Rothschild Holding S.A.
Edmond DE Rothschild Holding S.A. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 3.8% in the 3rd quarter, according to its most recent disclosure with the Secu
Truist Financial Sticks to Their Buy Rating for Gilead Sciences (GILD)
Robert W. Baird Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $80.00
Gilead Sciences (NASDAQ:GILD – Get Rating) had its price objective lifted by Robert W. Baird from $69.00 to $80.00 in a research note released on Friday morning, The Fly reports. Other equities analy
Company Overview
More
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
CEO： Mr. Daniel O’Day
Market： NASDAQ
Listing Date： 01/22/1992
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet